optimist wrote:I thought the risk of anaphalactic shock is in the first few infusions. Why would this only show up after one had been getting infusions for more than one year and thus in the two year data if it is indeed there?
A very good question indeed!!
Monoclonal antibodies, in general, present the greatest danger of anaphalactic shock during the first or second infusion. That's why the FDA insists on the highest level of warning for this class of drug (the black box, as it is called)
We simply don't know any of the circumstances around these two deaths of Tysabri infusions but hopefully someone can obtain this info and let us know the facts.